Skip to content

Released Aug 14, 2025, before the open

10-Q filed Aug 14, 2025, 45 days after period end · 0001558370-25-011471

Q2 2025 · 10-Q
Revenue$15.66M+16.2% vs Q2 2024+54.8% vs Q1 2025
Net Income$164.00KN/M vs Q2 2024N/M vs Q1 2025
EPS Diluted$0.00N/M vs Q2 2024N/M vs Q1 2025
Operating Income$1,172,000N/M
Operating Cash Flowderived-$5,233,000N/M
Free Cash Flowderived-$5,664,000N/M
Margins · derived
Operating margin7.5%+25.5 pt vs Q2 2024
Net margin1.0%+17.4 pt vs Q2 2024

What the release said

The release

Same quarter

MetricQ2 2025Q2 2024Q2 2023Q2 2022
Revenue$15.66M$13.47M$35.08M$8.75M
Net Income$164.00K-$2.20M$19.34M-$5.33M
EPS Diluted$0.00-$0.03$0.21-$0.11

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR